Healthcare Wire Texas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.

Press releases published on September 30, 2026

Sep. 30, 2026

PaRC Highlights Houston Addiction Treatment Programs for National Recovery Month

Indeterminate EIN Presswire

Sep. 30, 2026

Formaspace and Cramer to Showcase the Complete Lab Experience at HCD 2026

Indeterminate EIN Presswire

Sep. 30, 2026

Best Foot Forward Joins with Other Health Care Partners for Annual 'Paint the Gap' Event in San Antonio during MHPA26

Indeterminate EIN Presswire

Sep. 30, 2026

Sold-Out DM Summit 2026 Equips 440 Orthodontic Professionals to Transform Their Practices with Remote Monitoring

Indeterminate EIN Presswire

Sep. 30, 2026

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 30, 2026

Oculis Announces Resignation of Lionel Carnot from Board of Directors

Indeterminate GlobeNewswire

Sep. 30, 2026

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

Indeterminate GlobeNewswire

Sep. 30, 2026

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

Indeterminate GlobeNewswire

Sep. 30, 2026

Standard BioTools Provides Update on Sale of Mass Cytometry Business

Indeterminate GlobeNewswire

Sep. 30, 2026

TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness

Indeterminate GlobeNewswire

Sep. 30, 2026

Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements

Indeterminate GlobeNewswire

Sep. 30, 2026

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

Indeterminate GlobeNewswire

Sep. 30, 2026

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Indeterminate GlobeNewswire

Sep. 30, 2026

Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026

Indeterminate GlobeNewswire

Sep. 30, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

Indeterminate GlobeNewswire

Sep. 30, 2026

Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis

Indeterminate GlobeNewswire

Sep. 30, 2026

Scienture Holdings, Inc. Announces Reverse Stock Split

Indeterminate GlobeNewswire

Sep. 30, 2026

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

Indeterminate GlobeNewswire

Sep. 30, 2026

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

Indeterminate GlobeNewswire

Sep. 30, 2026

Type 2 Diabetes Doesn’t Have to Be Your Future: Medicare Has a Benefit That Can Help

Indeterminate GlobeNewswire